Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.

22 in total

Review 1. Genetic studies in pediatric ITP: outlook, feasibility, and requirements.

Authors: Anke K Bergmann; Rachael F Grace; Ellis J Neufeld
Journal: Ann Hematol Date: 2010-03-23 Impact factor: 3.673

Review 2. Rituximab resistance.

Authors: Andrew R Rezvani; David G Maloney
Journal: Best Pract Res Clin Haematol Date: 2011-04-13 Impact factor: 3.020

3. The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.

Authors: Manfred Ahlgrimm; Michael Pfreundschuh; Markus Kreuz; Evi Regitz; Klaus-Dieter Preuss; Joerg Bittenbring
Journal: Blood Date: 2011-09-07 Impact factor: 22.113

4. Examining racial differences in diffuse large B-cell lymphoma presentation and survival.

Authors: Christopher R Flowers; Pareen J Shenoy; Uma Borate; Kevin Bumpers; Tanyanika Douglas-Holland; Nassoma King; Otis W Brawley; Joseph Lipscomb; Mary Jo Lechowicz; Rajni Sinha; Rajinder S Grover; Leon Bernal-Mizrachi; Jeanne Kowalski; Will Donnellan; Angelina The; Vishnu Reddy; David L Jaye; James Foran
Journal: Leuk Lymphoma Date: 2013-02

5. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.

Authors: Robert A Baiocchi; Lapo Alinari; Mark E Lustberg; Thomas S Lin; Pierluigi Porcu; Xiaobai Li; Jeffrey S Johnston; John C Byrd; Kristie A Blum
Journal: Cancer Date: 2010-12-14 Impact factor: 6.860

6. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.

Authors: Wen-Kai Weng; Robert S Negrin; Philip Lavori; Sandra J Horning
Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544

Review 7. Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms.

Authors: Wasif Riaz; Francisco J Hernandez-Ilizaliturri; Myron S Czuczman
Journal: Immunol Res Date: 2010-03 Impact factor: 2.829

8. FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.

Authors: Fen Liu; Huirong Ding; Xuan Jin; Ning Ding; Lijuan Deng; Yan He; Jun Zhu; Yuqin Song
Journal: DNA Cell Biol Date: 2014-07-22 Impact factor: 3.311

9. Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20⁺ B Cell Malignancies.

Authors: Noa Granot; Andrew R Rezvani; Barbara S Pender; Barry E Storer; Brenda M Sandmaier; Rainer Storb; David G Maloney
Journal: Biol Blood Marrow Transplant Date: 2020-07-18 Impact factor: 5.742

10. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.

Authors: Andrés López-Albaitero; Steve C Lee; Sarah Morgan; Jennifer R Grandis; William E Gooding; Soldano Ferrone; Robert L Ferris
Journal: Cancer Immunol Immunother Date: 2009-03-25 Impact factor: 6.968